Symmetra Biosciences

Symmetra Biosciences is a biotechnology company focused on the emerging field of glycobiology to develop next-generation cancer immunotherapies. Founded by Nobel Laureate Carolyn Bertozzi, the company targets the glyco-immune checkpoint, a mechanism where cancer cells use surface sugars called glycans to evade immune detection. Symmetra's platform identifies specific glycan-protein interactions that suppress immune responses, particularly those involving Siglec receptors on myeloid cells and NK cells. By developing antibodies that block these interactions, the company aims to restore the immune system's ability to attack solid tumors. Their approach represents a novel frontier in precision oncology, aiming to provide solutions for patients who are resistant to current PD-1/PD-L1 therapies.